The "Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, In-situ Hybridization, Microarray)- Forecast to 2021" report has been added to Research and Markets' offering.

The cancer/tumor profiling market is primarily driven by the increasing number of cancer cases, growing utility of biomarkers in tumor profiling, and availability of funding for cancer research. In addition, the introduction and adoption of point-of-care diagnostic tests and development of personalized medicine are expected to offer growth opportunities for manufacturers of cancer/tumor profiling solutions. However, high capital investments and low benefit ratio of biomarkers are restraining the growth of this market.

On the basis of technology, the global cancer/tumor profiling market is broadly divided into immunoassays, hybridization, NGS, mass spectrometry, and other technologies. In 2017, the immunoassays segment is expected to account for the largest share of the cancer/tumor profiling technologies market. The high sensitivity and cost-effectiveness of these techniques as well as technological advancements in these immunoassays tests are factors that are expected to propel the growth of this market in the coming years. Furthermore, the hybridization technology is again divided on the basis of type which includes PCR, in-situ hybridization, and microarrays. The PCR segment is expected to account for the largest market share of hybridization technology in 2017. PCR is one of the most widely used technologies in the diagnostics market. This is primarily due to its ease of use, cost-effectiveness, quick turnaround time (4 to 6 hours), and easy availability of kits and reagents.

Key Topics Covered:

  • Market Overview
  • Cancer/Tumor Profiling Market, By Technology
  • Cancer/Tumor Profiling Market, By Cancer Type
  • Cancer/Tumor Profiling Market, By Application
  • Cancer/Tumor Profiling Market, By Region 10 Competitive Landscape

Companies Mentioned

  • Caris Life Sciences
  • Genomic Health Inc.
  • Helomics Corporation
  • Htg Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • Neogenomics Laboratories, Inc.
  • Oxford Gene Technology
  • Qiagen N.V.
  • Ribomed Biotechnologies, Inc

For more information about this report visit https://www.researchandmarkets.com/research/26qtfk/global?w=4